Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaougou, I.en
dc.contributor.authorMarkatseli, T. E.en
dc.contributor.authorVoulgari, P. V.en
dc.contributor.authorDrosos, A. A.en
dc.rightsDefault Licence-
dc.subjectAntibodies, Monoclonal/administration & dosage/adverse effects/*therapeutic useen
dc.subjectAntirheumatic Agents/administration & dosage/adverse effects/*therapeutic useen
dc.subjectC-Reactive Protein/metabolismen
dc.subjectDose-Response Relationship, Drugen
dc.subjectInjections, Intravenousen
dc.subjectLongitudinal Studiesen
dc.subjectMiddle Ageden
dc.subjectRetrospective Studiesen
dc.subjectSpondylitis, Ankylosing/blood/*drug therapyen
dc.subjectTreatment Outcomeen
dc.subjectTumor Necrosis Factor-alpha/antagonists & inhibitorsen
dc.titleMaintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term studyen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractOBJECTIVES: To investigate the efficacy, safety and drug discontinuation in patients with ankylosing spondylitis treated with infliximab, as well as the drug survival over a period of 6 years. METHODS: Forty patients with ankylosing spondylitis treated with infliximab were included in this open label study. All patients fulfilled the New York revised criteria for ankylosing spondylitis. Infliximab was given intravenously (5 mg/kg/body weight) at weeks 0, 2, 6 and every 8 weeks thereafter for a period of 6 years. Data concerning infliximab efficacy, tolerability, adverse events and drug discontinuation, were recorded. Clinical improvement according to the Bath Ankylosing Spondylitis Disease Activity Index 50% and the Ankylosing Spondylitis Assessment Study Group 20% and 40% were also recorded. RESULTS: A significant improvement in the Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Assessment Study Group scores was noted in the first year which sustained through the sixth year of treatment. More specifically, after the sixth year of treatment, Bath Ankylosing Spondylitis Disease Activity Index 50% was achieved by 65% of patients (26/40), Ankylosing Spondylitis Assessment Study Group 20% by 72.5% (29/40) and Ankylosing Spondylitis Assessment Study Group 40% was reached by 70% (28/40) of patients. Clinical improvement was associated with the reduction of acute phase reactants, such as C-reactive protein levels. After the first and the second year of treatment, the survival rate of infliximab reached 95%, after the third year it was 80%, while after the fourth year it was 72.5%, which was maintained throughout the fifth and sixth year of therapy. Five patients were increased the dose of infliximab and three of them had shortened the interval infusion. Overall, 11 patients were withdrawn during the observational period, three because of adverse events, two because of lack of efficacy, while six were lost from follow-up. CONCLUSION: Infliximab was effective, safe and well-tolerated in patients with ankylosing spondylitis. The clinical response was maintained for a period of 6 years, with high infliximab survival rate, reaching the percentage of 72.5%.en
heal.journalNameJoint Bone Spineen
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Saougou-2010-Maintained clinical.pdf399.52 kBAdobe PDFView/Open    Request a copy

This item is licensed under a Creative Commons License Creative Commons